Radius Health Archives -

AstraZeneca seems to have dodged the problems besetting other developers of oral selective oestrogen receptor degrader (SERD) drugs

After setbacks for Roche and Sanofi, AZ scores oral SERD win

https://pharmaphorum.com/news/after-setbacks-for-roche-and-sanofi-az-scores-oral-serd-win/

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline

End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial

https://pharmaphorum.com/news/end-of-the-line-for-sanofis-serd-amcenestrant-as-it-fails-first-line-trial/

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial

Roche’s oral SERD giredestrant fails breast cancer trial

https://pharmaphorum.com/news/roches-oral-serd-giredestrant-fails-breast-cancer-trial/

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from

Pfizer puts up $1bn to buy into Arvinas breast cancer programme

https://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/

But romosozumab missed secondary endpoint of non-vertebral fractures

Amgen/UCB reveal new osteoporosis drug data

https://pharmaphorum.com/news/amgenucb-reveal-new-osteoporosis-drug-data/

Radius Health